199 related articles for article (PubMed ID: 10052960)
1. Major groove binding and 'DNA-induced' fit in the intercalation of a derivative of the mixed topoisomerase I/II poison N-(2-(dimethylamino)ethyl)acridine-4-carboxamide (DACA) into DNA: X-ray structure complexed to d(CG(5-BrU)ACG)2 at 1.3-A resolution.
Todd AK; Adams A; Thorpe JH; Denny WA; Wakelin LP; Cardin CJ
J Med Chem; 1999 Feb; 42(4):536-40. PubMed ID: 10052960
[No Abstract] [Full Text] [Related]
2. Crystal structure of the topoisomerase II poison 9-amino-[N-(2-dimethylamino)ethyl]acridine-4-carboxamide bound to the DNA hexanucleotide d(CGTACG)2.
Adams A; Guss JM; Collyer CA; Denny WA; Wakelin LP
Biochemistry; 1999 Jul; 38(29):9221-33. PubMed ID: 10413496
[TBL] [Abstract][Full Text] [Related]
3. Structure of 9-amino-[N-(2-dimethylamino)propyl]acridine-4-carboxamide bound to d(CGTACG)(2): a comparison of structures of d(CGTACG)(2) complexed with intercalatorsin the presence of cobalt.
Adams A; Guss JM; Denny WA; Wakelin LP
Acta Crystallogr D Biol Crystallogr; 2004 May; 60(Pt 5):823-8. PubMed ID: 15103127
[TBL] [Abstract][Full Text] [Related]
4. 5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity.
Spicer JA; Finlay GJ; Baguley BC; Velea L; Graves DE; Denny WA
Anticancer Drug Des; 1999 Feb; 14(1):37-45. PubMed ID: 10363026
[TBL] [Abstract][Full Text] [Related]
5. Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Haldane A; Finlay GJ; Hay MP; Denny WA; Baguley BC
Anticancer Drug Des; 1999 Jun; 14(3):275-80. PubMed ID: 10500502
[TBL] [Abstract][Full Text] [Related]
6. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells.
Hicks KO; Pruijn FB; Baguley BC; Wilson WR
J Pharmacol Exp Ther; 2001 Jun; 297(3):1088-98. PubMed ID: 11356933
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Spicer JA; Gamage SA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1997 Jun; 40(12):1919-29. PubMed ID: 9191970
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
10. Kinetic studies of the binding of acridinecarboxamide topoisomerase poisons to DNA: implications for mode of binding of ligands with uncharged chromophores.
Wakelin LP; Adams A; Denny WA
J Med Chem; 2002 Feb; 45(4):894-901. PubMed ID: 11831901
[TBL] [Abstract][Full Text] [Related]
11. A molecular modeling study of B-DNA-intercalation complexes with amsacrine and related 9-anilino-acridines.
Fischer G; Pindur U
Pharmazie; 1999 Feb; 54(2):83-93. PubMed ID: 10084153
[TBL] [Abstract][Full Text] [Related]
12. Solution structural study of a DNA duplex containing the guanine-N7 adduct formed by a cytotoxic platinum-acridine hybrid agent.
Baruah H; Wright MW; Bierbach U
Biochemistry; 2005 Apr; 44(16):6059-70. PubMed ID: 15835895
[TBL] [Abstract][Full Text] [Related]
13. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
Finlay GJ; Riou JF; Baguley BC
Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277
[TBL] [Abstract][Full Text] [Related]
14. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.
Osman S; Rowlinson-Busza G; Luthra SK; Aboagye EO; Brown GD; Brady F; Myers R; Gamage SA; Denny WA; Baguley BC; Price PM
Cancer Res; 2001 Apr; 61(7):2935-44. PubMed ID: 11306471
[TBL] [Abstract][Full Text] [Related]
15. In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
Wolf SJ; Wakelin LP; He Z; Stewart BW; Catchpoole DR
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1059-69. PubMed ID: 19277661
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of 9-amino-N-[2-(4-morpholinyl)ethyl]-4-acridinecarboxamide bound to d(CGTACG)2: implications for structure-activity relationships of acridinecarboxamide topoisomerase poisons.
Adams A; Guss JM; Denny WA; Wakelin LP
Nucleic Acids Res; 2002 Feb; 30(3):719-25. PubMed ID: 11809884
[TBL] [Abstract][Full Text] [Related]
17. 4-Hydroxymethyl-3-aminoacridine derivatives as a new family of anticancer agents.
Charmantray F; Demeunynck M; Carrez D; Croisy A; Lansiaux A; Bailly C; Colson P
J Med Chem; 2003 Mar; 46(6):967-77. PubMed ID: 12620073
[TBL] [Abstract][Full Text] [Related]
18. Differential selection of acridine resistance mutations in human DNA topoisomerase IIbeta is dependent on the acridine structure.
Leontiou C; Watters GP; Gilroy KL; Heslop P; Cowell IG; Craig K; Lightowlers RN; Lakey JH; Austin CA
Mol Pharmacol; 2007 Apr; 71(4):1006-14. PubMed ID: 17209120
[TBL] [Abstract][Full Text] [Related]
19. Binding of a macrocyclic bisacridine and ametantrone to CGTACG involves similar unusual intercalation platforms.
Yang XL; Robinson H; Gao YG; Wang AH
Biochemistry; 2000 Sep; 39(36):10950-7. PubMed ID: 10998231
[TBL] [Abstract][Full Text] [Related]
20. Metal-intercalator-mediated self-association and one-dimensional aggregation in the structure of the excised major DNA adduct of a platinum-acridine agent.
Baruah H; Day CS; Wright MW; Bierbach U
J Am Chem Soc; 2004 Apr; 126(14):4492-3. PubMed ID: 15070347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
